Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
Molecular Diagnosis and Treatment of Leukemia
share announcement

Molecular Diagnosis and Treatment of Leukemia

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 December 2020) | Viewed by 1509

Special Issue Editor

Dr. Ancuta Jurj

E-Mail Website
Guest Editor
Research Center for Functional Genomics, Biomedicine and Translational Medicine, "Iuliu Hațieganu" University of Medicine and Pharmacy, 400337 Cluj-Napoca, Romania
Interests: drug resistance; exosomes; biomarkers; personalized medicine; nucleic acid
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

In the last several decades the field of leukemia has seen important advancements in the diagnosis, classification, and treatment of these patients. One of the first cornerstones in this regard is represented by the discovery that the BCR-ABL fusion is frequently present in chronic myeloid leukemia, and that it can be targeted with single-agent non-chemotherapy represented by imatinib. Since then, this approach has been extended to other leukemia, such as  acute myeloid leukemia, acute lymphoblastic leukemia, myeloproliferative neoplasms, and others. At present, most hospitals offer mutational analysis for genes like FLT3, JAK2, CALR, and MPL, to name a few. This has advanced in other hospitals with the existence of comprehensive gene panels that can better assess the prognosis of each patient.

Thus, the current Special Issue will be taking papers assessing the use of a variety of molecular markers in leukemia biology, diagnosis, prognosis, and treatment.

Dr. Ancuta Jurj
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Molecular diagnosis
  • Prognostic factors
  • Targeted therapy
  • Leukemia

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

11 pages, 3158 KiB  
Article
Immunophenotype of Measurable Residual Blast Cells as an Additional Prognostic Factor in Adults with B-Cell Acute Lymphoblastic Leukemia
by Yulia Davydova, Irina Galtseva, Nikolay Kapranov, Ksenia Nikiforova, Olga Aleshina, Yulia Chabaeva, Galina Isinova, Ekaterina Kotova, Andrey Sokolov, Vera Troitskaya, Sergey Kulikov and Elena Parovichnikova
Diagnostics 2023, 13(1), 21; https://0-doi-org.brum.beds.ac.uk/10.3390/diagnostics13010021 - 21 Dec 2022
Viewed by 1097
Abstract
Measurable residual disease (MRD) is a well-known independent prognostic factor in acute leukemias, and multicolor flow cytometry (MFC) is widely used to detect MRD. MFC is able not only to enumerate MRD accurately but also to describe an antigen expression profile of residual [...] Read more.
Measurable residual disease (MRD) is a well-known independent prognostic factor in acute leukemias, and multicolor flow cytometry (MFC) is widely used to detect MRD. MFC is able not only to enumerate MRD accurately but also to describe an antigen expression profile of residual blast cells. However, the relationship between MRD immunophenotype and patient survival probability has not yet been studied. We determined the prognostic impact of MRD immunophenotype in adults with B-cell acute lymphoblastic leukemia (B-ALL). In a multicenter study RALL-2016 (NCT03462095), 267 patients were enrolled from 2016 to 2022. MRD was assessed at the end of induction (day 70) in 94 patients with B-ALL by six- or 10-color flow cytometry in the bone marrow specimens. The 4 year relapse-free survival (RFS) was lower in MRD-positive B-ALL patients [37% vs. 78% (p < 0.0001)]. The absence of CD10, positive expression of CD38, and high expression of CD58 on MRD cells worsened the 4 year RFS [19% vs. 51% (p = 0.004), 0% vs. 51% (p < 0.0001), and 21% vs. 40% (p = 0.02), respectively]. The MRD immunophenotype is associated with RFS and could be an additional prognostic factor for B-ALL patients. Full article
(This article belongs to the Special Issue Molecular Diagnosis and Treatment of Leukemia)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop